Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Dexmedetomidine & EC50 of Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II patients who were 20-65 years old and scheduled for general anaesthesia for urologic surgery~Exclusion Criteria:~* Patients with an allergy to alpha-2 adrenergic agonists or propofol~* Patients who anticipated difficult airway (cervical spinal disease, Mallampati score of III or IV, a mouth opening of \<2.5 cm, and/or body mass index of \>30 kg m-2), unstable teeth~* Patients with bradycardia of \<50 beats/min, heart block greater than first degree, severe cardiorespiratory dysfunction~* Patients with symptoms of upper respiratory infection

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group D : Dexmedetomidine + propofol group (Type: EXPERIMENTAL): In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
- Group C : Saline + propofol group (Type: PLACEBO_COMPARATOR): In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).